Re­gen­eron ditch­es high­er dose of pain drug fas­inum­ab in PhI­II, trig­ger­ing safe­ty scare; In a small win for Al­ny­lam, FDA de­lays re­view for Ion­is' in­ot­ersen

→ Re­gen­eron $REGN has canned its high dose arm of fas­inum­ab, an os­teoarthri­tis and back pain drug be­ing test­ed in Phase III tri­als, fol­low­ing rec­om­men­da­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.